Halozyme Therapeutics Files 8-K with Key Agreements and Securities Info
Ticker: HALO · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.001, $1,500.0 million, $750.0 million, $100.0 million, $1.47 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-securities
Related Tickers: HALO
TL;DR
Halozyme dropped an 8-K detailing a new material agreement, financial obligation, and unregistered equity sales.
AI Summary
On November 6, 2025, Halozyme Therapeutics, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. Specific details regarding the agreement, financial obligation, and equity sales were filed with the SEC.
Why It Matters
This filing indicates significant corporate actions, including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities and new financial obligations, which can introduce financial and regulatory risks.
Key Players & Entities
- Halozyme Therapeutics, Inc. (company) — Registrant
- November 6, 2025 (date) — Date of Earliest Event Reported
FAQ
What is the nature of the material definitive agreement entered into by Halozyme Therapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details are not provided in the provided text.
What type of direct financial obligation was created by Halozyme Therapeutics?
The filing states the creation of a direct financial obligation, but the specific terms and amount are not detailed in the provided text.
What were the circumstances surrounding the unregistered sales of equity securities?
The filing reports unregistered sales of equity securities, but the details of these sales are not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 6, 2025.
What is Halozyme Therapeutics, Inc.'s Commission File Number?
Halozyme Therapeutics, Inc.'s Commission File Number is 001-32335.
Filing Stats: 2,958 words · 12 min read · ~10 pages · Grade level 15.2 · Accepted 2025-11-12 17:17:17
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Mar
- $1,500.0 million — pleted its previously announced sale of $1,500.0 million aggregate principal amount convertible
- $750.0 million — ertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031
- $100.0 million — " 2031 Convertible Notes "), including $100.0 million in aggregate principal amount of its 20
- $1.47 billion — eeds from the offering of approximately $1.47 billion after deducting the Initial Purchasers'
- $182.7 million — xpenses. The Company used approximately $182.7 million of the net proceeds of the offering to
- $1.020 billion — rchases, the Company paid approximately $1.020 billion in cash, which includes accrued interes
- $1,000 — eriod ") in which the trading price per $1,000 principal amount of notes for each trad
- $87.20 — to a conversion price of approximately $87.20 per share of common stock. The conversi
- $50.0 million — btedness for money borrowed of at least $50.0 million (or its foreign currency equivalent) in
- $136.78 — e Capped Call Transactions is initially $136.78 per share of common stock, representing
Filing Documents
- d945920d8k.htm (8-K) — 48KB
- d945920dex41.htm (EX-4.1) — 602KB
- d945920dex43.htm (EX-4.3) — 625KB
- d945920dex101.htm (EX-10.1) — 232KB
- g945920g1112041118580.jpg (GRAPHIC) — 2KB
- g945920g1112041118717.jpg (GRAPHIC) — 2KB
- g945920g1112041118851.jpg (GRAPHIC) — 2KB
- g945920g1112041118986.jpg (GRAPHIC) — 2KB
- g945920g1112041119125.jpg (GRAPHIC) — 2KB
- g945920g1112041119334.jpg (GRAPHIC) — 3KB
- 0001193125-25-277988.txt ( ) — 1920KB
- halo-20251106.xsd (EX-101.SCH) — 3KB
- halo-20251106_lab.xml (EX-101.LAB) — 17KB
- halo-20251106_pre.xml (EX-101.PRE) — 11KB
- d945920d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document Description 4.1 2031 Convertible Notes Indenture, dated November 12, 2025 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee. 4.2 Form of 0% Convertible Senior Notes due 2031 (included in Exhibit 4.1 hereto). 4.3 2032 Convertible Notes Indenture, dated November 12, 2025 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee. 4.4 Form of 0.875% Convertible Senior Notes due 2032 (included in Exhibit 4.3 hereto). 10.1 Form of Capped Call Confirmation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. Date: November 12, 2025 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Chief Financial Officer [ Signature Page to Form 8-K ]